{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:58:52Z","timestamp":1781143132427,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.lungcan.2026.109428","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T23:38:57Z","timestamp":1777333137000},"page":"109428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy"],"prefix":"10.1016","volume":"217","author":[{"given":"Masahiro","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4393-9176","authenticated-orcid":false,"given":"Ryo","family":"Ariyasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Fujishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Iso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyujiro","family":"Nibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhisa","family":"Nemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-2196","authenticated-orcid":false,"given":"Mayu","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Tsugitomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3242-0662","authenticated-orcid":false,"given":"Yoshiaki","family":"Amino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Uchibori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yanagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2026.109428_b0005","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109428_b0010","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2026.109428_b0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0020","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2026.109428_b0035","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1136\/jcp.53.7.537","article-title":"Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category","volume":"53","author":"Edwards","year":"2000","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lungcan.2026.109428_b0040","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/JTO.0b013e31820b86cb","article-title":"Accuracy of fine needle aspiration cytology in the pathological typing of non-small cell lung cancer","volume":"6","author":"Nizzoli","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0045","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/JTO.0000000000000264","article-title":"Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study","volume":"9","author":"Thunnissen","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0050","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1746-1596-9-103","article-title":"Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between \u201csquamous\u201d and \u201cnon-squamous\u201d cell carcinoma","volume":"9","author":"Yamagishi","year":"2014","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.lungcan.2026.109428_b0055","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0169-5002(00)00125-2","article-title":"Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines","volume":"30","author":"Dohmoto","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0060","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1082>3.0.CO;2-T","article-title":"The role of caspase 3 in producing cytokeratin 19 fragment (CYFRA21-1) in human lung cancer cell lines","volume":"91","author":"Dohmoto","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0065","article-title":"21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value","volume":"1","author":"Garcia-Valdecasas Gayo","year":"2020","journal-title":"Adv. Lab. Med."},{"key":"10.1016\/j.lungcan.2026.109428_b0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1378\/chest.108.1.163","article-title":"Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role","volume":"108","author":"Wieskopf","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2026.109428_b0075","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1097-0142(19930801)72:3<707::AID-CNCR2820720313>3.0.CO;2-X","article-title":"CYFRA 21-1. A new marker in lung cancer","volume":"72","author":"Stieber","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0080","doi-asserted-by":"crossref","DOI":"10.1177\/1010428318760420","article-title":"CYFRA 21-1 predicts the efficacy of nivolumab in patients with advanced lung adenocarcinoma","volume":"40","author":"Shirasu","year":"2018","journal-title":"Tumour Biol."},{"key":"10.1016\/j.lungcan.2026.109428_b0085","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","article-title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients","volume":"17","author":"Dal Bello","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2026.109428_b0090","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920952994","article-title":"CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors","volume":"12","author":"Dall\u2019Olio","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213712","article-title":"Serum CYFRA 21-1 as a prognostic marker in non-small-cell lung cancer patients treated with immune checkpoint inhibitors","volume":"16","author":"Miyadera","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lungcan.2026.109428_b0100","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.21037\/tlcr-24-190","article-title":"CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study","volume":"13","author":"Kataoka","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2026.109428_b0105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.tranon.2018.05.008","article-title":"Increased CYFRA 21-1, CEA and NSE are prognostic of poor outcome for locally advanced squamous cell carcinoma in lung: a nomogram and recursive partitioning risk stratification analysis","volume":"11","author":"Wang","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.21873\/invivo.11555","article-title":"Prognostic value of serum tumor markers in patients with stage III NSCLC treated with chemoradiotherapy","volume":"33","author":"Tokito","year":"2019","journal-title":"In Vivo"},{"key":"10.1016\/j.lungcan.2026.109428_b0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.radonc.2016.04.024","article-title":"Prognostic value of blood-biomarkers related to hypoxia, inflammation, immune response and tumour load in non-small cell lung cancer - a survival model with external validation","volume":"119","author":"Carvalho","year":"2016","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0120","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/s12885-015-1403-x","article-title":"The relationship between Glasgow Prognostic score and serum tumor markers in patients with advanced non-small cell lung cancer","volume":"15","author":"Jiang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0125","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.rmed.2003.11.003","article-title":"Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer","volume":"98","author":"Barl\u00e9si","year":"2004","journal-title":"Respir. Med."},{"key":"10.1016\/j.lungcan.2026.109428_b0130","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.cllc.2011.03.019","article-title":"Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)","volume":"12","author":"Cedr\u00e9s","year":"2011","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0135","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1038\/sj.bjc.6601851","article-title":"CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients","volume":"90","author":"Pujol","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0140","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1093\/clinchem\/48.11.1931","article-title":"Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients","volume":"48","author":"Kulpa","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.lungcan.2026.109428_b0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2012.45.2011","article-title":"Liquid biopsies: genotyping circulating tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2026.109428_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105226","article-title":"Prognostic significance of circulating tumor DNA as a baseline or dynamic factor in advanced NSCLC without oncogenic drivers: a systematic review and meta-analysis","volume":"221","author":"Andersen","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.lungcan.2026.109428_b0155","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond","volume":"124","author":"Keller","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2026.109428_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T01:15:52Z","timestamp":1781140552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":32,"alternative-id":["S0169500226004897"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109428","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of serum CYFRA21-1 in locally advanced non-small cell lung cancer undergoing durvalumab consolidation therapy after chemoradiotherapy","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109428"}}